InsidersTradesSigma
Total declarations
Company
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Rombotis Spiro George, Chief Executive Officer. Director active across 1 companies, notably Cyclacel Pharmaceuticals, Inc.. In total, 2 disclosures have been published. Total volume traded: €32k. The latest transaction was filed on 18 November 2021 — Acquisition. Regulator: SEC (Form 4). All data is accessible without signup.
Declarations2 total
€15,8994,000 shares@ €3.9748100.0% of flow
Common Stock
SEC:0001104659-21-142474·
Ideal exit: 15 Aug 2022 (T+270)
€15,8994,000 shares@ €3.974850.0% of flow
Common Stock
SEC:0001104659-21-142474:0·
Ideal exit: 15 Aug 2022 (T+270)
2 of 2 declarations
About Rombotis Spiro George
Spiro George Rombotis serves as President and CEO of Cyclacel Pharmaceuticals, Inc. He leads the strategic operations and ensures the growth of the company. His leadership is essential in advancing Cyclacel's mission, which focuses on developing innovative treatments. With extensive experience in the biopharmaceutical sector, Mr. Rombotis plays a key role in innovation and enhancing healthcare services.
